6 results
To investigate what the ideal moment to vaccinate would be, early (after 2-6 months) or late (after 9-12 months) after cessation of rituximab. Secondly to study the immune-response to vaccination with influenza virus vaccine after treatment with…
Primary objective;Confirm superiority of IgG antibody levels against pertussis toxin (Ptx), present in the acellular vaccines, in infants at the age of 3 months of mothers having received a pertussis vaccine during pregnancy versus infants of…
Primary: To evaluate the efficacy of tisagenlecleucel therapy as measured by overall response rate by investigator assessment.Secondary: Duration of response, event free survival, relapse free survival, overall survival, safety, kinetics,…
Primary objective:To investigate Pertussis Toxin (PT) specific antibody responses 1 month following the second aP vaccine given at 5 months of age to infants whose mothers have (Arm 1) or have not (Arm 2) received a pertussis booster vaccine during…
The primary objectives of this study are to assess the safety and estimate the radiation dose of the radioligand [18F]FB610, and to assess the optimal kinetic model for quantification of the tracer uptake. Secondary objectives are to determine…
The hypothesis of this study is that the regular topical application of Oxofulleram in patients with rosacea results in a reduction of the clinical symptoms.